Astria Therapeutics Inc Preliminary Results From The Phase 1a Clinical Trial Of STAR-0215 Transcript
Good day, and welcome to the Astria Therapeutics Phase Ia results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker, Ms. Andrea Matthews, Senior Vice President of Corporate Affairs. Please go ahead.
Thank you. Welcome to today's Astria Therapeutics' STAR-0215 Phase Ia results conference call. With me today are Jill Milne, Chief Executive Officer; Christopher Morabito, Chief Medical Officer; Andy Nichols, Chief Scientific Officer; Andrew Komjathy, Chief Commercial Officer; and Noah Clauser, Chief Financial Officer.
We issued a press release this morning summarizing the results from our Phase Ia trial with the STAR-0215 program, which is available on our website. We are also using slides during today's call that are available within the webcast and on the Events & Presentations section of our website.
I would like to note that during today's event,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |